-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatocellular carcinoma (HCC) is the sixth most common tumor in the world and the third most common cause of cancer-related deaths.
although treatment strategies such as surgical excision, arterial chemotherapy embolism, radio frequency ablation and liver transplantation have made great progress, the five-year survival rate of HCC is still less than 10%.
due to the diagnosis of late stage and the recurrence of the disease and other factors, resulting in poor prognosis of liver cancer.
, it is particularly important to further study the mechanisms involved in the development of HCC and to identify new HCC diagnostic markers.
SPATS2 is predicted to be a cytorna binding protein, initially found in the testes and playing a vital role in sperm production.
SPATS2 was involved in the development of a variety of malignant tumors.
the level of expression of SPATS2 in HCC and the associated molecular function are still not fully clear.
study on miR-145-5p/SPATS2 pathology in HCC to regulate apoptosis and cell cycles aims to reveal the expression spectrum and functional role of SPATS2 in liver cancer, and to explore the related regulatory role of SPATS2.
found that SPATS2 showed high levels of expression in HCC tissue compared to neighboring normal tissues.
high expression level of SPATS2 is also closely related to vascular immersion, late TNM stage, tumor diversity and poor survival rate.
SPATS2 showed that SPATS2 promoted the proliferation and metastasis of HCC cells in HCC tissue and was associated with poor prognosis in HCC patients, while knocking out SPATS2 enhanced apoptosis of HCC cells and blocked cell cycles in G1.
bioinsynomic analysis shows that MiR-145-5p can directly target SPATS2, while the functional rescue rescue experiment shows that over-expression MiR-145-5p can eliminate the regulation of SPATS2 on HCC malignancy.
(knocking down SPATS2 can inhibit the malignancy of liver cancer cells), the results reveal the role of SPATS2 in HCC cancer genes.
MiR-145-5p/SPATS2 path also provides a potential new mechanism for the development of HCC, which can be used as a potential therapeutic target for HCC.
.
